Previous 10 | Next 10 |
SAN DIEGO , May 28, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $50.00 per share. All of the shares are being sold by Arena. The gr...
SAN DIEGO , May 27, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offere...
SAN DIEGO , May 26, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 2b ADVISE trial evaluating etrasimod, an investigational next-generation, once-daily, oral, highly selective sphingosine 1-phosph...
SAN DIEGO , May 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that, due to public health and safety concerns related to the COVID-19 global pandemic, recommendations and orders from federal, state and local authorities, and to support ...
Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals Succeeds Magnus Persson, who oversaw period of rapid growth and success for Galecto Appoints David Shapiro MD, former CMO of Intercept Pharmaceuticals, to Board of Directors ...
Image source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA) Q1 2020 Earnings Call May 7, 2020 , 4:30 p.m. ET Operator Continue reading
Arena Pharmaceuticals, Inc. (ARNA) Q1 2020 Results Conference Call May 7, 2020 4:30 PM ET Company Participants Laurie Stelzer - CFO Amit Munshi - President & CEO Preston Klassen - Head R&D Conference Call Participants Jim Birchenough - Wells Fargo Kennen MacKa...
Arena Pharmaceuticals (NASDAQ: ARNA ): Q1 GAAP EPS of -$2.00 beats by $0.29 . More news on: Arena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2020 . "We are pleased to announce that our ongoing clinical programs are currently on track ...
Arena Pharmaceuticals (NASDAQ: ARNA ) is scheduled to announce Q1 earnings results on Thursday, May 7th, after market close. The consensus EPS Estimate is -$2.42 vs. $12.10 in 1Q19 and the consensus Revenue Estimate is $1.58M vs. $801M in 1Q19. Over the last 2 years, ARNA has bea...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...